Sensei Biotherapeutics (NASDAQ:FTH) Stock Price Target Lowered at Guggenheim

Sensei Biotherapeutics (NASDAQ:FTH) had its price objective reduced by investment analysts at Guggenheim from $70.00 to $69.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim‘s target price points to a potential upside of 253.59% from the stock’s previous close.

A number of other brokerages have also recently commented on FTH. Oppenheimer began coverage on Sensei Biotherapeutics in a research report on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Monday, September 14th. JonesTrading started coverage on shares of Sensei Biotherapeutics in a research note on Tuesday, August 4th. They issued a “buy” rating and a $55.00 target price on the stock. TD Cowen assumed coverage on Sensei Biotherapeutics in a report on Wednesday, September 9th. They issued a “buy” rating for the company. Finally, Wall Street Zen lowered Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, September 26th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $56.17.

Sensei Biotherapeutics Trading Down 0.7%

NASDAQ FTH traded down $0.14 during trading on Wednesday, hitting $19.51. The company had a trading volume of 6,028 shares, compared to its average volume of 251,458. Sensei Biotherapeutics has a one year low of $7.45 and a one year high of $42.14. The firm has a market capitalization of $504.24 million, a P/E ratio of -0.14 and a beta of -0.15. The stock has a fifty day simple moving average of $28.24.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its earnings results on Tuesday, November 3rd. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.13). As a group, equities research analysts expect that Sensei Biotherapeutics will post -13.69 EPS for the current fiscal year.

Institutional Trading of Sensei Biotherapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vivo Capital LLC purchased a new position in shares of Sensei Biotherapeutics in the first quarter valued at approximately $22,758,000. Candriam S.C.A. purchased a new position in Sensei Biotherapeutics in the 3rd quarter valued at approximately $9,542,000. Alyeska Investment Group L.P. acquired a new position in shares of Sensei Biotherapeutics in the second quarter worth $3,610,000. Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics in the first quarter worth $4,188,000. Finally, Bank of America Corp DE increased its position in shares of Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after acquiring an additional 32,719 shares during the period. 10.50% of the stock is currently owned by hedge funds and other institutional investors.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.